336 reports of this reaction
2.4% of all DAPTOMYCIN reports
#6 most reported adverse reaction
RHABDOMYOLYSIS is the #6 most commonly reported adverse reaction for DAPTOMYCIN, manufactured by APOTEX CORP.. There are 336 FDA adverse event reports linking DAPTOMYCIN to RHABDOMYOLYSIS. This represents approximately 2.4% of all 14,068 adverse event reports for this drug.
Patients taking DAPTOMYCIN who experience rhabdomyolysis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RHABDOMYOLYSIS is a less commonly reported adverse event for DAPTOMYCIN, but still significant enough to appear in the safety profile.
In addition to rhabdomyolysis, the following adverse reactions have been reported for DAPTOMYCIN:
The following drugs have also been linked to rhabdomyolysis in FDA adverse event reports:
RHABDOMYOLYSIS has been reported as an adverse event in 336 FDA reports for DAPTOMYCIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
RHABDOMYOLYSIS accounts for approximately 2.4% of all adverse event reports for DAPTOMYCIN, making it a notable side effect.
If you experience rhabdomyolysis while taking DAPTOMYCIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.